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Abstract 
Antiangiogenic treatment using bevacizumab may cause difficulties in distinguishing 
between antivascular and true antitumor effects when using MRI response criteria based on 
changes of contrast enhancement (i.e., Macdonald criteria). Furthermore, more precise 
tumor response assessment criteria (i.e., RANO criteria), which incorporate nonenhancing 
T2/FLAIR sequences into Macdonald criteria, may be influenced by other causes of T2/FLAIR 
hyperintensity (e.g., radiation-induced gliosis). The authors present discrepant MR and 
[18F]fluoroethyl-L-tyrosine PET imaging findings in a patient with bevacizumab treatment 
failure. 
 
Introduction 
Bevacizumab is thought to normalize tumor vasculature and restore the blood-brain 
barrier, decreasing contrast enhancement and peritumoral edema [1]. Conventional 
measurements of tumor response using MRI rely upon dimensions of enhancing tumor. 
Antiangiogenic treatment targeting the VEGF pathway using bevacizumab causes a 
rapid decrease in T1 contrast-enhancing tumor parts, with high radiographic response 
rates ranging between 30–60% [1]. However, in one third of all patients, glioblastomas 
are more prone to progress as nonenhancing tumor after bevacizumab treatment [2]. 
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Recently defined RANO (Response Assessment in Neuro-Oncology) criteria for 
glioma progression recommend fluid-attenuated inversion recovery (FLAIR)/T2 
hyperintensity on MRI as a surrogate for nonenhancing tumor; however, nonenhancing 
tumor can be difficult to differentiate from other causes of FLAIR/T2 hyperintensity 
(e.g., radiation-induced gliosis, peritumoral edema) [3]. Positron emission tomography 
using the radiolabeled amino acid O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET PET) may 
offer an improvement of the detection of ‘true’, i.e., metabolically active tumor extent of 
high-grade glioma over and above the information provided by contrast enhancement 
and FLAIR hyperintensity on MRI alone.  
Case Report 
A 58-year-old patient suffered from aphasia and agitation 4 weeks prior to admission. Initial MRI 
revealed a contrast-enhancing, tumor-suspicious lesion in the left temporal lobe, and a biopsy was 
performed stereotactically. Histopathologic findings confirmed a glioblastoma. Molecular analysis of 
prognostic factors revealed that the O6-methylguanine methyltransferase promoter (MGMT) was 
not methylated and isocitrate dehydrogenases 1 and 2 (IDH1/IDH2) were not mutated. In order 
to achieve a macroscopically complete tumor resection, a fluorescence-guided resection using 
5-aminolevulinic acid (5-ALA) was performed. After surgery, fractionated external radiation therapy 
was initiated. Within 2 weeks after tumor resection, the aphasia improved substantially. After 
stratification for molecular markers, the patient was treated with concomitant radiotherapy up to a 
dosage of 60 Gy, and afterwards with adjuvant bevacizumab [4] every 2 weeks over 8 months. Due to 
a severe allergic reaction, the combination therapy with irinotecan had to be discontinued after the 
first application. During bevacizumab treatment, clinical controls and follow-up MRIs in 8- to 12-week 
intervals showed no signs of tumor recurrence. 
After 8 months of single bevacizumab therapy, hemiparesis of the right side and deterioration of 
the aphasia occurred. The follow-up T1-weighted MRI (fig. 1a) demonstrates slight contrast 
enhancement within the left temporal lobe. In contrast, the hyperintensity on the FLAIR-weighted 
MRI (fig. 1b, encircled within black lines) is significantly larger, suggesting signs of nonenhancing 
tumor progression during bevacizumab treatment [2, 5]. To further evaluate the MRI results, 18F-FET 
PET (fig. 1d) was performed. Metabolically active tumor volume of 18F-FET PET uptake at a threshold 
≥1.6 and volume of the hyperintense FLAIR signal were calculated [6, 7] (fig. 1c, e). 
Coregistrations of 18F-FET PET scan (fig. 1d), contrast-enhanced and FLAIR-weighted MRI (fig. 1a, 
b), and volume of the FLAIR lesion (fig. 1c) and the metabolically active tumor (fig. 1d, encircled 
within white lines; e) show that the volume of the FLAIR hyperintensity is considerably larger than 
the metabolically active tumor volume. However, on superimposed images (fig. 1f), the volume of the 
FLAIR hyperintensity (grey) shows no correspondence in size and spatial configuration to the 18F-FET 
PET metabolically active tumor volume. Moreover, in comparison to the FLAIR hyperintensity, 
18F-FET uptake at a threshold ≥1.6 (red) reveals additional subareas of metabolically active tumor 
(fig. 1f) in transaxial, coronal, and sagittal orientation. 
For treatment of tumor recurrence, chemotherapy with dose-intensified temozolomide was 
initiated according to a 1 week on/1 week off regimen [8]. Clinically, chemotherapy response could 
not be observed; during follow-up an exacerbation of the aphasia and hemiparesis occurred. Due to a 
severe impairment of the patient’s clinical condition, palliative care was initiated 3 months after 
tumor recurrence.  
Discussion 
The differences in MRI and 18F-FET PET might be explained by a complex 
morphologic heterogeneity of glioblastoma, leading to difficult interpretation of 
standard MRI sequences. There are highly malignant tumor parts with and 
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without contrast enhancement, and, furthermore, T2-based signal hyperintensity 
is a combination of infiltrating tumor cells, necrotic areas, tumor edema, and 
treatment-related leukoencephalopathy, e.g., due to radiotherapy [3]. In contrast, 
18F-FET PET shows metabolically active tumor independent of any anatomic or 
pathophysiologic changes and may therefore reflect tumor extension more accurately 
than MRI [6]. In this context, localization of the 18F-FET PET metabolically active tumor 
does not always match the pathological findings seen on MRIs. For example, in a small 
group of patients with recurrent high-grade glioma treated with bevacizumab and 
irinotecan, which partially responded according to RANO criteria without response 
based on 18F-FET PET imaging findings, tumor progression could be detected earlier by 
18F-FET PET [9]. 
In summary, during bevacizumab treatment, 18F-FET PET in addition to 
contrast-enhanced and FLAIR-/T2-weighted MRI might add important information 
for assessment of tumor recurrence, as compared with standard MRI alone. 
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Fig. 1. Coregistered MR, 18F-FET PET, and superimposed images of the metabolically active tumor 
volume (red) at an 18F-FET uptake index threshold of ≥1.6 (red) and volume of FLAIR hyperintensity 
(white). FLAIR hyperintensity is not always located exclusively within the subareas of the tumor 
positive on 18F-FET PET. On superimposed pictures (bottom), FLAIR hyperintensity (grey) is 
eccentric and located partially outside the metabolically active tumor volume (red). VOI = Volume of 
interest; SUV = standardized uptake value. 
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